10.23.25 -- Is Italy A Quiet Outsourcing Standout For Drug Manufacturing?

The results herein highlight thermofluor screening as a versatile and efficient platform for rational formulation of injectable biologics through the acceleration of stable drug product development.

Discover how early intervention in antibody-drug conjugates (ADCs) development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.

Whether you're in the early stages of development or scaling up for commercialization, understanding ADC manufacturing challenges is essential for bringing life-saving therapies to patients worldwide.

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “CMOT Report” to our readers, identifying CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

No two tech transfers are the same. To ensure success with yours, learn how to select a CDMO that will be astute in their onboarding analysis and commit to ongoing collaboration.

Explore how formulation expertise can help overcome the complex challenges of developing stable, effective, and regulatory-compliant emulsifiable concentrate (EC) formulations for crop protection.

Ensure the potency and efficacy of your biologic products with a GMP-compliant potency bioassay, offering accurate real-time assessments for GMP release and stability testing.

Unlocking the potential of next-generation therapeutics requires extending the boundaries of both expression system technology and process development and manufacturing.

Drug developers must successfully navigate the path to market, under the growing pressure of regulation and competition, and while carefully managing technical and financial risk.

Experts share how surging demand for GLP-1 and other therapeutics is transforming fill/finish capacity and regulatory standards, and how CDMOs are adapting to the complex needs of new modalities.

With a proven track record, our flexible, client-focused model ensures seamless integration with internal teams and third-party vendors, delivering high satisfaction and long-term partnerships.

BD Neopak™ XSi™ Glass Prefillable Syringes have been designed for improved integrity of the lubricant layer, reducing subvisible particle level of biologic formulation in PFSs.

Simon Westbrook formed Levicept to develop an idea for a complex fusion chimera protein he believed could interrupt the neurotrophin pathway, and being a true virtual company, he needed a CDMO.

Detra Glinatsis, Vice President of Business Development, presents the advanced capabilities, strategic growth, and expanding capacity of Northway Biotech, a global biologics CDMO.

By leveraging our proprietary non-viral gene insertion technology, GPEx® Lightning ensures rapid development timelines and high-yield production, making it an ideal solution for complex biologics.